The omicron single-dose booster shot for children under the age of five was approved by Pfizer and its partner BioNTech SE by the US Food and Drug Administration (FDA). According to the agency, children who have already received three doses of the initial vaccine will be eligible for the booster.
After receiving the clinical trial data for sixty children in the aforementioned group, the FDA claimed that the emergency use authorisation (EUA) was granted. The new booster dose was given to the children who had already received the previous three doses.
According to Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, this authorization gives parents and caregivers of children aged 6 months to 4 years who received the three-dose primary series with the monovalent Pfizer-BioNTech COVID-19 Vaccine the opportunity to update their children’s protection by receiving a booster dose with the Pfizer-BioNTech COVID-19 Vaccine. The immune systems of the children demonstrated effective protection against both the original COVID-19 strain and
In particular, Moderna’s primary series of COVID-19 vaccines for children only contains two doses, whereas Pfizer’s primary series contains three doses.
Data indicate that children have received their first doses of the vaccine extremely slowly. The primary vaccination series is only available to 2.7% of children under the age of two and 5% of children between the ages of two and four.
